Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. (DYN) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
dyn · stock forecast · 14 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 14 Wall Street analysts in the past 3 months
Buy
14 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$47.00
Consensus
$34.86
+105.5% upside
Low
$23.00
Median: $38 · Last Close: $16.96
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$34.86
105.5% upside
High Target
$47
177.1%
Low Target
$23
35.6%
Current Price
$16.96
as of today
Based on analyst price targets, the DYN stock price prediction for the next 12 months ranges from $23 to $47. The consensus DYN price forecast of $34.86 implies 105.5% upside from the current price of $16.96.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $16.77 | ↓ 1.11% |
1-day model range: $16.64–$16.9. Peak: $16.9 (-1.11%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · DYN · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-15 | Evercore ISI Group | Maintains | Outperform→Outperform |
| 2026-05-13 | Bernstein | Maintains | Market Perform→Market Perform |
| 2026-03-09 | Chardan Capital | Maintains | Buy→Buy |
| 2026-03-03 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2026-03-03 | Chardan Capital | Maintains | Buy→Buy |
| 2026-03-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-01-20 | JP Morgan | Maintains | Neutral→Neutral |
| 2025-12-15 | Evercore ISI Group | Maintains | Outperform→Outperform |
| 2025-12-11 | Stifel | Maintains | Buy→Buy |
| 2025-12-10 | Oppenheimer | Upgrade ↑ | Perform→Outperform |
Wall Street analysts have recently issued updated ratings on Dyne Therapeutics, Inc. (DYN) stock. Of the recent 79 rating actions, 3 were upgrades and 2 were downgrades. 14 analysts currently cover DYN.
Analyst Recommendation Trends
DYN analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 99.7% YoY
Revenue Next Year
$51M
↑ 5050.8% YoY
EPS This Year
$-3.08
EPS Next Year
$-2.94
↓ 4.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast DYN EPS of $-3.08 for the current fiscal year, based on estimates from 12 analysts. The DYN revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The DYN stock forecast is supported by two independent data sources: analyst consensus ratings from 14 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus DYN price target is $34.86 (+105.5% upside), with an analyst consensus of Buy.
The DYN short-term stock prediction for tomorrow is $16.77 (-1.11%).
Dyne Therapeutics, Inc. trades on NASDAQ under the ticker DYN. The DYN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 86% of covering analysts.
Frequently asked questions
DYN forecast · 8 questionsAccording to 14 Wall Street analysts, the average 12-month DYN price target is $34.86, with a high forecast of $47.00 and a low of $23.00. The median price target is shown in the chart above when available. This implies +105.5% potential upside from the current price of $16.96.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.